Document:

EX-4.2

 Exhibit 4.2 
 TVAX BIOMEDICAL, LLC 
 AMENDED AND RESTATED WARRANT PURCHASE AGREEMENT

 THIS AMENDED AND RESTATED WARRANT PURCHASE AGREEMENT (the “Agreement”) is dated as of July 15,
2011, among TVAX Biomedical, LLC, a Missouri limited liability company (the “Company”), TVAX Biomedical, Inc. (“Parent”), the Persons listed on the Schedule of Purchasers attached hereto, the holders of the
Convertible Warrant listed on the Schedule of Contingent Warrant Holders attached hereto and each of the other holders of Warrants or Underlying Equity, if any, who become a party hereto in accordance with the terms hereof (collectively, the
“Purchasers” and individually, a “Purchaser”). 
 WHEREAS, the Company and the Purchasers are
parties to that certain Note and Warrant Purchase Agreement, dated as of January 15, 2010 (the “2010 Purchase Agreement”); 
 WHEREAS, pursuant to the terms of the 2010 Purchase Agreement, the Company issued and sold to the Purchasers (i) its 8% Senior Secured Convertible Notes in an aggregate principal amount of
$2,000,391.49 (the “Notes”); and (ii) its Warrants to acquire an aggregate of 1,333,594.32 units of Preferred Equity (the “Original Warrants”); 

WHEREAS, the 2010 Purchase Agreement was amended as of June 30, 2010 to reflect the execution and delivery of the Investment
Compliance Agreement; 
 WHEREAS, the Board of Managers of the Company has determined that it is in the best interest of the
Company and its members to undertake the consummation of an underwritten public offering pursuant to an effective registration statement filed by the Parent or the Company (or any successor entity to the Company) with the Securities and Exchange
Commission under the Securities Act with respect to common equity of the Parent or the Company (or any successor entity to the Company) (the “Public Offering”); 

WHEREAS, in lieu of interest that would accrue on the Notes from July 15, 2011 to the original Note termination date, the Company
shall issue to Investors or individually to its members (to the extent of an election to convert the Notes to Series C Preferred Units) a five-year contingent warrant to purchase up to 109,148 Series C Preferred Units at $1.50, which would become
exercisable only for such period of time (i) commencing on the earlier of either (A) the close of business on September 30, 2012 if the Parent has not completed a Public Offering prior to that time, or (B) the date of a Change in
Control of the Company or Parent that occurs prior to September 30, 2012, and (ii) ending on the Expiration Date (the “Contingent Warrant”, and along with the Original Warrants, the “Warrants”);

 WHEREAS, the holder of the Notes has agreed with the Company to convert 100% of the Notes and, in order to consummate the
conversion, the Company and the Purchaser desire to amend the 2010 Purchase Agreement to remove the provisions relating to the Notes; 
 WHEREAS, as a result of the conversion of the Note, the security interest granted pursuant to the 2010 Purchase Agreement will be terminated; 

  
 1 

 NOW THEREFORE, in consideration for the terms and conditions herein stated, the parties
agree to amend and restate the 2010 Purchase Agreement, as amended, in its entirety as follows: 
 Section 1.
Definitions and Related Matters. 
 1.1 Definitions. For the purposes of this Agreement, the following terms have
the meanings set forth below: 
 “Affiliate” of any particular party means: (i) any other party which
directly or indirectly, controls or is controlling by or is under common control with such party and (ii) any officer, director, manager, managing partner or member of such party or any other party holding a similar position with respect to
such party. A party shall be deemed to be “controlled by” any other party if such other party possesses, directly or indirectly, power to vote 5% or more of the securities (on a fully diluted basis) having ordinary voting power for
the election of directors, managers or managing partners or power to direct or cause the direction of the management and policies of such party whether by contract or otherwise. 

“Change in Control” means any sale, transfer or issuance or series of sales or issuances of the Company’s Equity
Interests or the equity interests of Parent, or any merger, consolidation or other transaction involving the Company or Parent, immediately after which the holder or holders of the Company’s Equity Interests or the equity interests of Parent,
as the case may be, immediately prior to such transaction or transactions no longer possess the voting power to elect a majority of the Company’s managers (or other governing board) or a majority of Parent’s board of directors, as the case
may be, or the holder or holders of the Company’s Equity Interests or the equity interests of Parent immediately prior to such transaction or transactions no longer hold record and beneficial ownership of at least a majority of the
Company’s voting Equity Securities or the voting equity interests of Parent, as the case may be. 

“Closing” shall mean the Initial Closing or the Subsequent Closing. 

“Code” shall mean the Internal Revenue Code of 1986, as amended. 

“Common Equity” means, collectively, the Company’s Common Units (as defined in the Operating Agreement) and any
equity securities of any class or series of the Company hereafter authorized or otherwise created that is not limited to a fixed sum or percentage of par or stated value in respect of the rights of the holders thereof to participate in
Distributions. 
 “Convertible Securities” of the Company means any securities (directly or indirectly)
convertible into or exchangeable for any Equity Interest of such Person, including all warrants, options and other rights to acquire any Equity Interests of the Company. 
 “Distributions” means any distribution by the Company with respect to its ownership interests whether in cash, securities (including common and preferred equity) or other property,
including distributions upon any liquidation, dissolution or winding up of the Company. 

  
 2 

 “Employment Agreement” shall mean each 3-year employment, non-competition
and non-solicitation agreement, dated as of January 15, 2010, between the Company and each Key Employee. 

“Environmental and Safety Requirements” means all federal, state, local and foreign statutes, regulations, ordinances
and similar provisions having the force or effect of law, all judicial and administrative orders and determinations, all contractual obligations and all common law, in each case concerning public health and safety, worker health and safety and
pollution or protection of the environment (including all those relating to the presence, use, production, generation, handling, transportation, treatment, storage, disposal, distribution, labeling, testing, processing, discharge, release,
threatened release, control or cleanup of any hazardous or otherwise regulated materials, substances or wastes, chemical substances or mixtures, pesticides, pollutants, contaminants, toxic chemicals, petroleum products or byproducts, asbestos,
polychlorinated biphenyls, noise or radiation), each as amended and as now or hereafter in effect. 
 “Equity
Interests” means all of the equity or other ownership interests in the Company (including Convertible Securities and other rights containing phantom or other equity participation features). 

“Equity Purchase” means any redemption, acquisition, purchase or other retirement of any Units. 

“ERISA” means the Employee Retirement Income Security Act of 1974 (or any successor legislation thereto) , as amended,
or any similar federal law then in force. 
 “Expiration Date” means the earlier of June __, 2016, or the
consummation a Public Offering prior to the close of business on September 30, 2012. 
 “GAAP” means
generally accepted accounting principles as promulgated by the Financial Accounting Standards Board and/or any other governing body or boards having jurisdiction, authority or responsibility for promulgating accounting standards, as in effect from
time to time. 
 “General Release” means each general release of liability executed and delivered on
January 15, 2010 by each of the Company’s employees, officer, managers, members and other Affiliates. 

“Governing Documents” of the Company means the Articles of Organization and Operating Agreement. 

“Indebtedness” means the aggregate amount of, without duplication: (i) all obligations of the Company or Parent for
borrowed money; (ii) all obligations of the Company or Parent evidenced by bonds, debentures, notes or other similar instruments; (iii) all obligations of the Company or Parent to pay the deferred purchase price of property or services;
(iv) all capital lease obligations of the Company or Parent; (v) all obligations or liabilities of any other Person secured by a Lien on any asset of the Company or Parent, whether or not such obligation or liability is assumed;
(vi) all obligations or liabilities of others guaranteed by the Company or Parent; and (vi) any other obligations or liabilities which are required by GAAP to be shown as debt on the balance sheet of the Company or Parent. 

  
 3 

 “Initial Closing” shall mean January 15, 2010. 

“Intellectual Property Rights” means all: (i) patents, patent applications, patent disclosures and inventions;
(ii) trademarks, service marks, trade dress, trade names, internet domain names, logos and corporate names and registrations and applications for registration thereof, together with all of the goodwill associated therewith;
(iii) copyrights (registered or unregistered) and copyrightable works and registrations and applications for registration thereof; (iv) mask works and registrations and applications for registration thereof; (v) computer software,
data, data bases and documentation thereof; (vi) trade secrets and other confidential information (including ideas, formulas, compositions, inventions (whether patentable or unpatentable and whether or not reduced to practice), know-how,
manufacturing and production processes and techniques, research and development information, drawings, specifications, designs, plans, proposals, technical data, copyrightable works, financial and marketing plans and customer and supplier lists and
information); (vii) other intellectual property rights; and (viii) copies and tangible embodiments thereof (in whatever form or medium). 
 “Investment” as applied to any Person means: (i) any direct or indirect purchase or other acquisition by such Person of any notes, obligations, instruments, Equity Interests and
other securities of any other Person; and (ii) any capital contribution by such Person to any other Person. 

“Investment Compliance Agreement” means that certain Investment Compliance Agreement, dated as of June 30, 2010 to
which Company, Purchaser and the Kansas Bioscience Authority are signatories. 
 “Investment Documents” means
this Agreement, the agreements and instruments evidencing the Warrants and the Underlying Equity (including the Operating Agreement), the Investor Rights Agreement, the General Releases, the Employment Agreements, the IP Agreements, the Investment
Compliance Agreement, Certificate of Incorporation of Parent and TVAX Holdings Partners, Inc., the operating agreement of TVAX Holdings, LLC and each of the other agreements, documents and instruments expressly contemplated hereby and thereby,
including the key-man life insurance policy required under Section 3.13. 
 “IP Agreement” shall mean each
proprietary information and inventions agreement, dated as of January 15, 2010, between the Company and each of its current and former employees and certain consultants including Catherine Lucasey, Timothy Wurst and Frank Holladay. 

“Key Employee” means Gary W. Wood and Rex E. Wiggins. 

“Knowledge” or “aware” regarding Company means and includes: (i) the actual knowledge or awareness
of the Company (which shall include the actual knowledge and awareness of the officers and managers of the Company, a Key Employee, Catherine Lucasey, Timothy Wurst and Frank Holladay); and (ii) the knowledge or awareness which a prudent
business person would have obtained in the conduct of his business after making reasonable inquiry and reasonable diligence with respect to the particular matter in question. 

  
 4 

 “Lead Investor” means TVAX Investors, LLC. 

“Liens” means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest,
encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, any lease in the nature of a security interest,
and the filing of any financing statement (other than a precautionary financing statement with respect to a lease that is not in the nature of a security interest) under the UCC or comparable law of any jurisdiction. 

“material” means any matter that, in the aggregate with all other matters, has resulted or might result in costs,
liabilities, expenses, damages or prospects of or to, or claims by or against the Company involving $25,000 or more. 

“Material Adverse Effect” means any matter or matters which would, alone or in the aggregate, have a materially adverse
effect on: (i) the operating results, prospects, assets, liabilities, operations, condition (financial or otherwise) or business of the Company or Parent; or (ii) the ability of the Company or Parent to perform any of their respective
obligations under the Warrants or any of the Investment Documents. 
 “Operating Agreement” means the Fourth
Amended and Restated Operating Agreement of the Company, dated as of the date hereof. 
 “Permitted Liens”
means: (i) Liens for taxes or other governmental charges not yet due and payable or which are being contested in good faith by appropriate proceedings and for which adequate reserves have been established by the Company in accordance with GAAP
consistently applied; and (ii) Liens arising in the ordinary course of business, consistent with past practice for sums not overdue or being contested in good faith by appropriate proceedings and not involving any deposits or advances or
borrowed money or the deferred purchase price of property or services and, in each case, for which the Company maintains adequate reserves. 
 “Person” means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization, a
governmental entity or any department, agency or political subdivision thereof and any other entity. 
 “Preferred
Equity” means the Company’s Series C Preferred Units having the rights, preferences and privileges set forth in the Operating Agreement. 
 “Securities” means the Notes and the Warrants collectively. 

“Securities Act” means the Securities Act of 1933, as amended, or any similar federal law then in force. 

“Securities and Exchange Commission” includes any governmental body or agency succeeding to the functions thereof.

  
 5 

 “Securities Exchange Act” means the Securities Exchange Act of 1934, as
amended, or any similar federal law then in force. 
 “Solvent” shall mean, with respect to any Person on any
date, that on such date: (i) the fair value of the assets of such Person is greater than the fair value of the liabilities (including contingent liabilities) of such Person, (ii) the present fair saleable value of the assets of such Person
is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured, (iii) such Person does not intend to, and does not believe that it will, incur debts or liabilities
beyond such Person’s ability to pay as such debts and liabilities mature, and (iv) such Person is not engaged in any business or transaction, and is not about to engage in any business or transaction, for which such Person’s property
would constitute an unreasonably small amount of capital for such business or transaction. 
 “Subsequent
Closing” shall mean the closing that occurred on July 23, 2010. 
 “Tax” or
“Taxes” means any federal, state, county, local, foreign or other income, gross receipts, ad valorem, franchise, profits, sales or use, transfer, registration, excise, utility, environmental, communications, real or personal
property, capital stock, license, payroll, wage or other withholding, employment, social security, severance, stamp, occupation, alternative or add-on minimum, estimated and other taxes of any kind whatsoever (including deficiencies, penalties,
additions to tax, and interest attributable thereto) whether disputed or not. 
 “Tax Return” means any return,
information report or filing with respect to Taxes, including any schedules attached thereto and including any amendment thereof 
 “UCC” means the Uniform Commercial Code as the same is, from time to time, in effect in the State of Missouri; provided, that in the event that, by reason of mandatory provisions
of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Purchasers’ Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other
than the State of Missouri, then the term “UCC” shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection,
priority or remedies and for purposes of definitions related to such provisions. Unless otherwise defined herein, terms that are defined in the UCC and used herein shall have the meanings given to them in the UCC. 

“Underlying Equity” means: (i) the securities issued or issuable upon exercise of the Warrants; (ii) the
securities issued or issuable upon the conversion of the securities referred to in clause (i); and (iii) any securities issued or issuable with respect to the securities referred to in clauses (i) or (ii) by way of Distribution or
split or in connection with a combination of securities, recapitalization, merger, consolidation or other reorganization. For purposes of this Agreement, any Person holding any Warrants shall be deemed to be the holder of the Underlying Equity
obtainable upon the conversion or exercise of the Warrants in connection with the transfer thereof or otherwise regardless of any restriction or limitation on the conversion or exercise of the Securities, such Underlying Equity shall be deemed to be
in existence, and such Person shall be entitled to exercise the rights of a holder of Underlying Equity hereunder. As to any particular 

  
 6 

 
units of Underlying Equity, such units shall cease to be Underlying Equity when they have been (a) effectively registered under the Securities Act and disposed of in accordance with the
registration statement covering them, (b) distributed to the public through a broker, dealer or market maker pursuant to Rule 144 under the Securities Act (or any similar provision then in force or (c) purchased by Company or any direct or
indirect subsidiary of Company. For the avoidance of doubt, Underlying Equity includes the Equity of Parent issued or issuable upon the exercise of the Warrants pursuant to the Operating Agreement of the Company and the operating agreement of TVAX
Holdings, LLC. 
 1.2 Interpretive Matters. In each of the Investment Documents, unless a clear contrary intention
appears: (i) the singular number includes the plural number and vice versa; (ii) reference to any Person includes such Person’s successors and assigns but, if applicable, only if such successors and assigns are permitted by such
Investment Document, and reference to a Person in a particular capacity excludes such Person in any other capacity or individually; (iii) reference to any gender includes each other gender; (iv) reference to any agreement (including this
Agreement and the Schedules and Exhibits hereto), document or instrument means such agreement, document or instrument as amended or modified and in effect from time to time in accordance with the terms thereof and, if applicable, the terms hereof
(and without giving effect to any amendment or modification that would not be permitted in accordance with the terms hereof); (v) reference to any applicable law, statute, rule or regulation means such applicable law, statute, rule or
regulation as amended, modified, codified or reenacted, in whole or in part, and in effect from time to time, including rules and regulations promulgated thereunder and reference to any particular provision of any applicable law, statute, rule or
regulation shall be interpreted to include any revision of or successor to that provision regardless of how numbered or classified; (vi) reference to any Article, Section, Schedule or Exhibit means such Article or Section hereof or such
Schedule or Exhibit hereto; (vii) “hereunder,” “hereof,” “hereto” and words of similar import shall be deemed references to this Agreement as a whole and not to any particular Section or other provision hereof;
(viii) “including” (and with correlative meaning “include”) means including without limiting the generality of any description preceding such term; and (ix) relative to the determining of any period of time,
“from” means “from and including” and “to” and “through” mean “to and including”; (x) “or”, “either” and “any” are not exclusive. 

Section 2. Authorization. 
 2.1 Authorization of the Securities. The Company shall authorize the issuance and sale to the Purchaser of the Contingent Warrant. 

2.2 Purchase and Sale of the Securities. Pursuant to the 2010 Purchase Agreement as amended on June 30, 2010, the Company has
issued the Original Warrants. In addition, on July 15, 2011, the Company shall issue to the Purchaser and, subject to the terms and conditions set forth herein, the Purchaser shall purchase from the Company the Contingent Warrant. 

  
 7 

 Section 3. Covenants. 

3.1 Financial Statements and Other Information. The Company shall furnish to each Purchaser (so long as such Purchaser owns any of
the Warrants or Underlying Equity): 
 (i) as soon as available but in any event within 30 days after the end of
each fiscal quarter in each fiscal year, unaudited statements of income and cash flows of the Company for such quarterly period and for the period from the beginning of the fiscal year to the end of such quarter, and unaudited balance sheets of the
Company as of the end of such quarterly period, all prepared in accordance with GAAP consistently applied, subject to the absence of footnote disclosures and to normal year-end adjustments for recurring accruals (none of which would, alone or in the
aggregate, have a Material Adverse Effect), and shall be certified by the Company’s chief financial officer; 
 (ii) within 90 days after the end of each fiscal year, audited statements of income and cash flows of the Company for such fiscal year, and a balance sheet of the Company as of the end of such fiscal
year, setting forth in each case comparisons to the Company’s preceding fiscal year, all prepared in accordance with GAAP consistently applied, and promptly upon receipt, a copy of such firm’s annual management letter to the Company’s
managers; 
 (iii) at least 30 days but not more than 90 days prior to the beginning of each fiscal year, an
annual budget prepared on a monthly basis for the Company for such fiscal year (displaying anticipated statements of income and cash flows and balance sheets), and promptly upon preparation thereof any other significant budgets prepared by the
Company and any revisions of such annual or other budgets, and within 30 days after any monthly period in which there is a material adverse deviation from the annual budget, a report of the Company’s chief financial officer explaining the
deviation and what actions the Company has taken and proposes to take with respect thereto; 
 (iv) promptly upon
receipt thereof, any additional reports, management letters or other detailed information concerning significant aspects of the Company’s operations or financial affairs given to the Company by its independent accountants (and not otherwise
contained in other materials provided hereunder); 
 (v) promptly (but in any event within 10 days) after the
discovery or receipt of notice of any default under any Investment Document or any other material agreement to which Company is a party, any investigation, notice, proceeding or adverse determination from any governmental or regulatory authority or
agency, or any other material adverse change, event or circumstance affecting the Company (including the filing of any litigation against the Company that could result in any material liability to the Company or the existence of any dispute with any
Person which involves a reasonable likelihood of such litigation being commenced), a report of the Company’s chief financial officer specifying the nature and period of existence thereof and what actions the Company has taken and proposes to
take with respect thereto; 
 (vi) promptly (but in any event within 10 days) after becoming aware of any other
event which might reasonably be expected to have a Material Adverse Effect, written notice thereof which describes the same and the intended course of action of the Company; 

  
 8 

 (vii) immediately after the receipt of notice (oral or written) of the
acceleration of any Indebtedness; and 
 (viii) with reasonable promptness, such other information and financial
data concerning the Company as any Purchaser may reasonably request. 
 Upon the consummation of a Public Offering, the
Company’s obligation to furnish the information set forth in subsections (i), (ii), (iii), (iv) and (viii) shall terminate. 
 3.2 Inspection of Property. The Company shall permit any representatives designated by any Purchaser, upon reasonable notice and during normal business hours and at such other times as any such
holder may reasonably request, to: (i) visit and inspect any of its properties; (ii) examine its company and financial records and make copies thereof or extracts therefrom; and (iii) discuss the affairs, finances and accounts of the
Company with its managers, officers, key employees and independent accountants. 
 3.3 Attendance at Board Meetings. The
Company shall give a representative or representatives of the Lead Investor (so long as such party continues to own, directly or indirectly, any of the Warrants or Underlying Equity) written notice of each meeting of its governing board as required
under the Operating Agreement, and the Company shall permit a representative or representatives of the Lead Investor to attend either in person or by telephone (at the election of such party) as an observer all meetings of its governing board. Each
representative shall be entitled to receive all written materials and other information (including copies of meeting minutes) given to members of the governing board in connection with such meetings at the same time such materials and information
are given to such members. If the Company proposes to take any action by written consent in lieu of a meeting of its governing board, the Company shall give written notice thereof to the Lead Investor (so long as such party continues to own,
directly or indirectly, any of the Warrants or Underlying Equity) prior to the effective date of such consent describing in reasonable detail the nature and substance of such action. The Company shall pay the reasonable out-of-pocket expenses of
each representative incurred in connection with attending all such meetings. The Company’s obligations set forth in this Section 3.3 shall terminate upon the consummation of a Public Offering. 

3.4 Affirmative Covenants. So long as any of the Warrants remain outstanding, the Company shall: 

(i) at all times cause to be done all things necessary to maintain, preserve and renew its company existence; 

(ii) maintain the key-man life insurance policy referred to in Section 3.13; and 

(iii) at all times reserve and keep available, free from preemptive rights, out of its authorized but unissued authorized
capital, solely for the purpose of issue upon exercise of Warrants as herein provided, such number of Series C Preferred Units as shall then be issuable upon the exercise of all Warrants issuable hereunder. 

  
 9 

 3.5 Negative Covenants. 

(i) In addition to any consent requirements for Preferred Equity contained in the Operating Agreement, so long as any of
the Warrants remain outstanding, the Company shall not directly or indirectly, without the prior written consent of the holders of outstanding Warrants representing 50% of the Preferred Equity subject to the outstanding Warrants, which consent shall
not be unreasonably withheld: 
 (a) liquidate, dissolve or wind-up its business and affairs or effect any
merger, consolidation, transfer of securities or other transaction resulting in a Change in Control, exclusive license or other disposition of substantially all of the assets of Company or any transaction or event similar to any of the foregoing;

 (b) make any amendment or alteration to or repeal the Governing Documents or any portion thereof whether by
merger, conversion, operation of law or otherwise or amend or modify or grant a waiver under or with respect to any Investment Documents; 
 (c) enter into, become subject to, amend, modify or waive any agreement or instrument which by its terms would (under any circumstances) restrict the Company’s ability to fulfill its obligations
under the Warrants or any of the other Investment Documents; 
 (d) make an election to treat the Company as a
corporation for federal or state income tax purposes other than in connection with a Qualified Public Offering (as that term is defined in the Operating Agreement); 

(e) take any action or fail to take any action that would materially and adversely affect the rights, preferences and
privileges of the Warrants; or 
 (f) agree to do any of the foregoing. 

(ii) In addition to any consent requirements for Preferred Equity contained in the Operating Agreement, prior to the
consummation of a Public Offering, the Company shall not directly or indirectly, without the prior written consent of the holders of outstanding Warrants representing 50% of the Preferred Equity subject to the outstanding Warrants, which consent
shall not be unreasonably withheld: 
 (a) liquidate, dissolve or wind-up its business and affairs, merge or
consolidate with any Person or convert to any other type of business entity or cause the conversion of any of its equity securities; 
 (b) make any amendment or alteration to or repeal this Agreement or the Articles, directly or indirectly, whether by merger, conversion, operation of law or otherwise; 

  
 10 

 (c) create or authorize the creation of any other security of the Company
convertible into or exercisable for any equity security, having rights, preferences or privileges senior to or on parity with the Series C Preferred Units; 
 (d) reclassify, alter or amend any equity security having rights, preferences or privileges junior to or on parity with the Series C Preferred Units; 

(e) make any Equity Purchase (other than in accordance with the Series C Warrants); or 

(f) agree to do any of the foregoing. 

3.6 Use of Proceeds; Engagement of Certain Parties; Capital Raising. The Company shall use the proceeds from
the sale of Securities solely for the development of the TVAX ImmunotherapySM treatment and the engagement of certain personnel and advisors in accordance with this Section and reimbursements and other payments to Purchasers required under this Agreement. Except as otherwise
provided in the Warrants or in Section 12.21 of the Operating Agreement, the Company may only issue Preferred Equity in exchange for capital contributions made in cash. 
 3.7 Underlying Equity. All Equity Interests which are so issuable upon the exercise of any Warrants or any Underlying Equity shall, when issued, be duly and validly issued, fully paid and
nonassessable and free from all Taxes and Liens. The Company shall take all such actions as may be necessary to assure that all such Equity Interests may be so issued without violation of any law, statute, rule or regulation to which the Company or
any requirements of any domestic securities exchange upon which such Equity Interests may be listed (except for official notice of issuance which shall be immediately transmitted by the Company upon issuance). This obligation shall continue to bind
any other Person obligated to issue any Equity Interests upon the exercise of any Warrants or upon the conversion or exercise of any Underlying Equity. 
 3.8 Intellectual Property Rights. The Company shall not take or fail to take any action which would result in the invalidity, abandonment, misuse or unenforceability of any of its Intellectual
Property Rights or which would infringe upon or misappropriate any rights of other Persons. 
 3.9 Further Assurances. At
any time and from time to time, upon the request of a Purchaser, the Company shall execute, deliver and acknowledge or cause to be executed, delivered and acknowledged, such further documents and instruments and do such other acts and things as so
requested in order to fully effect the purposes of this Agreement, the other Investment Documents and any other agreements, instruments and documents delivered pursuant hereto or in connection with the Warrants and the Underlying Equity. 

3.10 Treatment Services. The Company will provide each individual Purchaser and each individual record or beneficial owner of TVAX
Investors, LLC (including individuals that hold an indirect or beneficial interest in TVAX Investors, LLC through a trust, limited liability company, partnership or any other entity that is a member of TVAX Investors, LLC) and each such
individual’s parents, spouse, children and grandchildren and up to 25 of the officers, key employees, directors, managers or record or beneficial owners of any entity owner of TVAX 

  
 11 

 
Investors, LLC or any other entity Purchaser that participates in any Subsequent Closing with services for Company’s treatment methodology during their lifetimes free of charge after
approval of such treatment methodology by the U.S. Food and Drug Administration. The provisions of this Section 3.10 shall accrue to the benefit of successors and assigns of the Lead Investor. 

3.11 Current Public Information. At all times after the Company has filed a registration statement with the Securities and
Exchange Commission pursuant to the requirements of either the Securities Act or the Securities Exchange Act, the Company shall file all reports required to be filed by it under the Securities Act and the Securities Exchange Act and the rules and
regulations adopted by the Securities and Exchange Commission thereunder and shall take such further action as any holder or holders of Warrants or Underlying Equity may reasonably request, all to the extent required to enable such holders to sell
any such securities pursuant to Rule 144 adopted by the Securities and Exchange Commission under the Securities Act (as such rule may be amended from time to time) or any similar rule or regulation hereafter adopted by the Securities and Exchange
Commission. Upon request, Company shall deliver to any holder of such securities a written statement as to whether it has complied with such requirements. 
 3.12 Use of TVAX Name. The Company hereby unconditionally and irrevocably authorizes the Lead Investor to use “TVAX” in its company name free of charge. 

3.13 Key Man Policy. The Company shall maintain a key-man life insurance policy on the life of Gary W. Wood in the face amount of
$2,000,000. Such insurance policy shall name the TVAX Investor Trust as beneficiary and shall provide that such insurance policy may not be canceled unless the insurance carrier gives at least 30 days prior written notice of such cancellation to the
beneficiary. 
 Section 4. Representations and Warranties of the Company under 2010 Purchase Agreement. The
representations and warranties given by the Company as of the date of the Closing, as a material inducement to the Purchasers to enter into the 2010 Purchase Agreement are incorporated herein by reference to the 2010 Purchase Agreement as amended as
of June 30, 2010. The defined terms set forth in the 2010 Purchase Agreement are incorporated herein by reference into this Section 4 only. The schedules to the 2010 Purchase Agreement are incorporated herein by reference. 

Section 5. Representations and Warranties of the Company. As of the date of this Agreement, and as a material inducement to
the Purchasers to enter into this Agreement, the Company hereby represents and warrants to the Purchasers as follows: 
 5.1
Organization, Corporate Power and Licenses. The Company is a limited liability company duly organized, validly existing and in good standing under the laws of the state of Missouri, and is qualified to do business in every jurisdiction in
which its ownership of property or conduct of business requires it to qualify. The Company possesses all requisite company power and authority and all material licenses, permits and authorizations necessary to own and operate its properties, to
carry on its business as now conducted and presently proposed to be conducted and to carry out the transactions contemplated by the Investment Documents. 

  
 12 

 5.2 Authorization; No Breach. The execution, delivery and performance of the
Investment Documents and all other agreements and instruments contemplated hereby and thereby to which the Company is a party have been duly authorized by the Company. The Investment Documents constitute a valid and binding obligation of the
Company, enforceable in accordance with its terms. The execution and delivery by the Company of the Investment Documents, the offering, sale and issuance of the Warrants hereunder, the issuance of the Underlying Equity upon conversion or exercise of
the Warrants and Preferred Equity and the fulfillment of and compliance with the respective terms hereof and thereof by the Company, do not and shall not: (i) conflict with or result in a breach of the terms, conditions or provisions of
(ii) constitute a default under; (iii) result in the creation of any Lien upon the Company’s Equity Interests or assets pursuant to; (iv) give any third party the right to modify, terminate or accelerate any obligation under;
(v) result in a violation of or (vi) require any authorization, consent, approval, exemption or other action by or notice or declaration to, or filing with, any court or administrative or governmental body or agency or any third party
pursuant to, the Governing Documents, or any law, statute, rule or regulation to which the Company is subject, or any agreement, instrument, order, judgment or decree to which the Company is subject. 

5.3 Valid Issuance. As of the date of this Agreement, the Underlying Equity issuable upon exercise or conversion of the Warrants
and Preferred Equity will, when issued, be duly authorized and validly issued, fully paid and nonassessable. 
 Section 6.
Miscellaneous. 
 6.1 Expenses. The Company shall pay the attorneys’ fees and due diligence expenses of
Purchasers incurred by each of them in connection with the consummation of all of the transactions contemplated hereby and in the other Investment Documents, which costs and expenses shall be payable at each Closing and upon execution of this
Agreement. The Company shall pay all attorneys’ fees incurred by Purchasers with respect to any amendments or waivers (whether or not the same become effective) under or in respect of each of the Investment Documents. The Company shall also pay
all recording and filing fees, stamp and other transfer or document taxes which may be payable in respect of the execution and delivery of the Investment Documents or the issuance, delivery or acquisition of any Warrants or any Underlying Equity
issuable upon conversion or exercise of the Warrants or Preferred Equity. The Company shall pay the fees and expenses (including all attorneys’ fees) incurred by Purchasers with respect to the enforcement of the rights granted under the
Investment Documents and the agreements or instruments contemplated hereby and thereby (including costs of collection). In no event shall this provision include any requirement that the Company pay income or other similar taxes that are attributable
to Purchasers as a result of Purchasers’ consummation of all of the transactions contemplated hereby and thereby. Parent shall unconditionally guarantee the Company’s payment and performance in full of the Company’s obligations
pursuant to this Section 6.1. 
 6.2 Remedies. Each holder of Warrants and Underlying Equity shall have all rights
and remedies set forth in the Investment Documents and the Governing Documents and all rights and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights which such holders have under any
law, statute, rule or regulation. No remedy hereunder or thereunder conferred is intended to be exclusive of any other remedy, 

  
 13 

 
and each and every such remedy shall be cumulative and shall be in addition to every other remedy given hereunder or thereunder or now or hereafter existing at law or in equity or by statute or
otherwise. Purchasers shall be entitled to enforce their rights hereunder and under the Warrants specifically (without posting a bond or other security), to recover damages by reason of any breach of any provision hereof or thereof and to exercise
all other rights granted by law, statute, rule or regulation, subject to the restrictions or limitations contained in this Agreement. 
 6.3 Purchaser’s Investment Representations. 
 (i) The
representations and warranties given by the Purchasers in Section 8.3 of the 2010 Purchase Agreement as of the as of the date of the Closing, as a material inducement to the Company to enter into the 2010 Purchase Agreement are incorporated
herein by reference to the 2010 Purchase Agreement as amended as of June 30, 2010. 
 (ii) Each Purchaser of
Contingent Warrants, severally and not jointly, hereby represents that it is acquiring the Contingent Warrants purchased hereunder for its own account with the present intention of holding such securities for purposes of investment, and that it has
no intention of selling such securities in a public distribution in violation of the federal securities laws or any applicable state securities laws; provided, that, nothing contained herein shall prevent the transfer of such
securities in compliance with the Investment Documents and applicable securities laws. 
 6.4 Amendments and Waivers.
Except as otherwise expressly provided herein, the provisions of this Agreement may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, or waive the application of any
provision hereof only if the Company has obtained the prior written consent of the holders of Warrants representing 50% of the Underlying Equity issuable upon the exercise of the Warrants. No other course of dealing between the Company and the
holder of any Security or Underlying Equity or any delay in exercising any rights hereunder or under the Warrants or the Governing Documents or any other Investment Documents shall operate as waiver of any rights of any such holders. No Warrants or
Underlying Equity held by Company or any direct or indirect subsidiary of the Company shall be deemed to be outstanding for any purpose under this Agreement. If the Company pays any consideration to any holder of Warrants or Underlying Equity for
such holder’s consent to any amendment, modification or waiver hereunder, such party shall also pay each other holder granting its consent hereunder equivalent consideration computed on a pro rata basis. Any amendment, modification or waiver of
any rights granted in this Agreement to the Lead Investor requires the prior written consent of the Lead Investor. 
 6.5
Survival of Agreement. All covenants, representations and warranties contained in the Investment Documents or made by the Company in connection herewith or therewith shall survive the execution and delivery of the Investment Documents and the
consummation of the transactions contemplated hereby and thereby, regardless of any investigation made by any Purchaser or on its behalf. All covenants and obligations of the Company shall apply to the benefit of Purchasers and their successors and
assigns so long as any Warrants or Underlying Equity remains outstanding, including the covenants contained in Section 3. 

  
 14 

 6.6 No Setoffs, etc. All payments hereunder and under the Warrants shall be made by
the Company without setoff, offset, deduction or counterclaim, free and clear of all taxes, levies, imports, duties, fees and charges, and without any withholding, restriction or conditions imposed by any governmental authority. If the Company shall
be required by any law, statute, rule or regulation to deduct, setoff or withhold any amount from or in respect of any payment to any Purchaser hereunder or under the Warrants or any notes issued in exchange for any Warrants , then the amount so
payable to such Purchaser shall be increased as may be necessary so that, after making all required deductions, setoffs and withholdings, such Purchaser shall receive an amount equal to the sum they would have received had no such deductions,
setoffs or withholding been made. 
 6.7 Successors and Assigns. All covenants and agreements contained in this Agreement
by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and assigns of the parties hereto whether or not so expressed; provided, that the Company may not assign or delegate its rights or
obligations under this Agreement or under the Warrants . In addition, and whether or not any express assignment has been made, the provisions of this Agreement which are for any Purchaser’s benefit as a purchaser or holder of Warrants or
Underlying Equity are also for the benefit of, and enforceable by, any subsequent holder of the same (other than the Company or any direct or indirect subsidiary of the Company). Except as otherwise expressly provided herein, nothing expressed in or
implied from this Agreement is intended to give, or shall be construed to give, any Person, other than the parties hereto and their permitted successors and assigns, any benefit or legal or equitable right, remedy or claim under or by virtue of this
Agreement or any such other document. 
 6.8 Severability. Whenever possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such
prohibition or invalidity, without invalidating the remainder of this Agreement and shall be reformed and enforced to the maximum extent permitted under applicable law. 
 6.9 Counterparts. This Agreement may be executed in two or more counterparts, none of which need contain the signatures of more than one party, but all such counterparts taken together shall
constitute one and the same Agreement. 
 6.10 Descriptive Headings. The descriptive headings of this Agreement and the
Warrants are inserted for convenience only and do not constitute a substantive part of this Agreement. 
 6.11 Governing
Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Missouri, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Missouri or any other
jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Missouri. 
 6.12
Notices. All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given when delivered personally to the recipient, sent
to the recipient by reputable 

  
 15 

 
overnight courier service (charges prepaid), mailed to the recipient by certified or registered mail, return receipt requested and postage prepaid or sent via facsimile to the number set forth
below with a copy mailed to the recipient as set forth above. Such notices, demands and other communications shall be sent to the Purchasers and to the Company at the addresses indicated below: 

To the Company: 
 TVAX Biomedical, LLC 
 8060 Reeder Street 

Lenexa, Kansas 66214 
 Attn: Gary W. Wood 
 Facsimile: (913) 492-2243 

With a copy to: 
 Shook, Hardy & Bacon L.L.P. 
 2555 Grand Boulevard

 Kansas City, Missouri 64108 

Attn: Mareta J. Smith 
 Facsimile: (816) 421-5547 
 To the Purchasers: 

See Schedule of Purchasers 
 with a copy to: 
 Bryan Cave LLP 

3500 One Kansas City Place 
 1200 Main Street 
 Kansas City, Missouri 64105 

Attn: Robert M. Barnes 
 Facsimile: (816) 855-3368 
 or to such other address or to the attention of such other person
as the recipient party has specified by prior written notice to the sending party. 
 6.13 Construction. The parties
hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto, and no
presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. The parties intend that each representation, warranty and covenant contained herein shall have
independent significance. If any party has breached any representation, warranty or covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless of
the relative levels of specificity) which such party has not breached shall not detract from or mitigate the fact that such party is in breach of the first representation, warranty or covenant. 

  
 16 

 6.14 Complete Agreement. This Agreement, those documents expressly referred to
herein, and the other documents of even date herewith delivered or executed in connection with the transactions contemplated hereby embody the complete agreement and understanding among the parties and supersede any prior agreements or
representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way. 

6.15 Indemnification. In consideration of each Purchaser’s execution and delivery, of this Agreement and purchase the
Securities hereunder and in addition to all of the Company’s other obligations under this Agreement and in addition to all other rights and remedies available at law or in equity, the Company shall defend, protect and indemnify the Purchasers
and each other holder of Securities or Underlying Equity and all of their officers, managers, directors, stockholders, members, partners, limited partners, Affiliates, employees, agents, representatives, successors and assigns (including those
retained in connection with the transactions contemplated by this Agreement) (collectively, the “Indemnitees”), and save and hold each of them harmless from and against, and pay on behalf of or reimburse such party, on demand as and
when incurred, any and all actions, causes of action, suits, claims, losses (including diminutions in value and consequential damages), costs, penalties, fees, liabilities and damages and expenses in connection therewith (irrespective of whether any
such Indemnitee is a party to the action for which indemnification hereunder is sought), including reasonable attorneys’ fees and disbursements, interest and penalties and all amounts paid in investigation, defense or settlement of any of the
foregoing and claims relating to any of the foregoing (the “Liabilities”), incurred by the Indemnitees or any of them as a result of, or arising out of, or relating to: (i) any activities financed or to be financed in whole or
in part, directly or indirectly, with the proceeds of the issuance of the Securities; and (ii) any breach of any representation, covenant or agreement of the Company contained in this Agreement or any of the other Investment Documents, except
to the extent any such Liabilities are caused solely by the particular Indemnitee’s willful misconduct. 
 6.16 Payment
Set Aside. To the extent that any payment or payments are made to any Purchaser hereunder or under the Warrants and such payment or payments are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to such payor, a trustee, receiver or any other Person under any law, statute, rule or regulation (including any bankruptcy law, state or federal law, common law or equitable
cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or
setoff had not occurred. 
 6.17 Jurisdiction and Venue. Each of the parties: (i) submits to the jurisdiction of any
state or federal court sitting in Kansas City, Missouri in any legal suit, action or proceeding arising out of or relating to this Agreement or the Securities ; (ii) agrees that all claims in respect of the action or proceeding may be heard or
determined in any such court; and (iii) agrees not to bring any action or proceeding arising out of or relating to this Agreement or the Securities in any other court. Each of the parties waives any defense of inconvenient forum to the

  
 17 

 
maintenance of any action or proceeding so brought and waives any bond, surety or other security that might be required of any other party with respect thereto. Any party may make service on any
other party by sending or delivering a copy of the process to the party to be served at the address and in the manner provided for the giving of notices in Section 6.12. Each party agrees that a final judgment in any action or proceeding so
brought shall be conclusive and may be enforced by suit on the judgment or in any other manner provided by law. Nothing herein shall affect the right to serve process in any other manner permitted by law, statute, rule or regulation. Nothing herein
shall be deemed to preclude the enforcement of any judgment obtained in any other forum or the taking of any action to enforce the same in any other appropriate jurisdiction, and the parties waive the right to collaterally attack any such judgment
or action. 
 6.18 Waiver of Right to Jury Trial. THE PARTIES HEREBY WAIVE, TO THE EXTENT PERMITTED BY APPLICABLE LAW,
TRIAL BY JURY IN ANY LITIGATION IN ANY COURT WITH RESPECT TO, IN CONNECTION WITH, OR ARISING OUT OF THIS AGREEMENT OR THE SECURITIES OR THE VALIDITY, PROTECTION, INTERPRETATION, COLLECTION OR ENFORCEMENT THEREOF. THE PARTIES AGREE THAT THIS SECTION
IS A SPECIFIC AND MATERIAL ASPECT OF THIS AGREEMENT AND ACKNOWLEDGES THAT THE PURCHASERS WOULD NOT PURCHASE THE SECURITIES HEREUNDER IF THIS SECTION WERE NOT PART OF THIS AGREEMENT. 

6.19 Waiver. 
 (i) The Company shall give Purchasers prompt written notice after obtaining knowledge of the occurrence of any claim or cause of action that the Company believes it has, or may seek to assert to allege
against a Purchaser whether such claim is based in law or equity, arising under or related to this Agreement or any of the other Investment Documents or to the transactions contemplated hereby or thereby, or any act or omission to act by a Purchaser
with respect hereto or thereto, and that if the Company shall fail to give such notice to Purchasers with regard to any such claim or cause of action, the Company shall be deemed to have waived, and shall be forever barred from bringing or asserting
such claim or cause of action in any suit, action or proceeding in any court or before any governmental agency or authority or any arbitrator. 
 (ii) NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS AGREEMENT OR ANYWHERE ELSE, THE COMPANY AGREES THAT IT SHALL NOT SEEK FROM ANY PURCHASER UNDER ANY THEORY OF LIABILITY (INCLUDING ANY THEORY
IN TORTS), ANY SPECIAL, EXEMPLARY, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES. 
 6.20 Several Liability of
Purchasers. The liabilities and obligations of the Purchasers under the Investment Documents, including the Purchasers’ obligation to purchase the Warrants hereunder are several obligations of the Purchasers. No Purchaser shall have any
obligation or liability arising under any Investment Document or otherwise as a result of any other Purchaser’s breach or default hereunder or thereunder. THE COMPANY SHALL BE DEEMED TO HAVE WAIVED ANY SUCH ACTION, CLAIM, RIGHT OR CAUSE OF
ACTION ANY SUCH PARTY MAY HAVE AGAINST ANY SUCH PURCHASER. 
 [THIS SPACE
INTENTIONALLY LEFT BLANK; SIGNATURE PAGE FOLLOWS] 

  
 18 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the date first
written above. 
  

			
	COMPANY:
	
	TVAX BIOMEDICAL, LLC
		
	By:	 	/s/ Gary W. Wood
	Name:	 	Gary W. Wood
	Title:	 	President and Chief Executive Officer

  

			
	PARENT:
	
	TVAX BIOMEDICAL, INC.
		
	By:	 	/s/ Gary W. Wood
	Name:	 	Gary W. Wood
	Title:	 	President and Chief Executive Officer

  

			
	PURCHASER:
	
	TVAX INVESTORS, LLC
		
	By:	 	/s/ Larry C. Maddox
	Name:	 	Larry C. Maddox, Manager
	Title:	 	Managing Member

  
 19EX-4.3

 Exhibit 4.3 
 EXECUTION COPY 
 TVAX BIOMEDICAL, INC. 

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of July 15, 2011, by and among TVAX Biomedical, Inc., a Delaware corporation (the
“Company”), TVAX Biomedical I, LLC, a Missouri limited liability company (“Biomedical”), TVAX Investors, LLC, a Kansas limited liability company (“Investors”), and those parties to which Investors
distributes Series C Stock or a Series C Warrant (together with Investors, each an “Investor”), the holders of Series A Preferred Stock, the holders of Series B Preferred Stock, the holders of Series C Preferred Stock and the
holders of Common Stock and Junior Common Stock and any other party that subsequent to the date hereof executes a signature page to this Agreement as an “Other Stockholder” (collectively with the holders of Series A Preferred Stock, the
holders of Series B Preferred Stock, the holders of Series C Preferred Stock, the holders of Common Stock and Junior Common Stock, “Other Stockholders”). The Investors and Other Stockholders are sometimes collectively referred to
herein as “Equityholders”. Capitalized terms used in this Agreement and not expressly defined herein shall have the same meaning assigned to such term as in the Certificate of Incorporation of the Company, filed with the Secretary
of State of Delaware on July 14, 2011, as amended (“Certificate of Incorporation”). All provisions of this Agreement that apply to holders of Common Stock shall apply equally to holders of Junior Common Stock. 

WHEREAS, Biomedical, Investors and certain of the Other Stockholders entered into an Investor Rights Agreement dated January 15,
2010 (the “2010 Agreement”), for the purposes, among others, of (i) limiting the manner and terms by which Common Units of Founders and Executives could be transferred and (ii) providing certain Equityholders with certain
preemptive rights, registration rights and other rights; and 
 WHEREAS, Section 19 of the 2010 Agreement specifically
provided that the 2010 Agreement can be amended by a written instrument executed by Investors and Biomedical; and 
 WHEREAS,
Investors and Biomedical desire to amend and restate the 2010 Agreement to make the Company a party to the Agreement, to include provisions relating to the Common Stock, and to make the holders of Common Stock parties to the Agreement. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties to this Agreement hereby agree to amend and completely restate the 2010 Agreement as follows: 
 1. Restrictions on Transfer of Restricted Interests. Sections 1 and 2 shall apply to any Transfer of any Equity Interests held, directly or indirectly, by Founders or any Executive (the
“Subject Equityholders”) until a Public Offering or an Approved Sale (but shall not apply to such Public Offering or Approved Sale). For the avoidance of doubt, Sections 1 and 2 shall not apply to any Transfer of Equity Interests of
an Investor or holder of Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock, including the Transfer of Series C Warrants, Equity Interests issued upon the exercise of Series C Warrants or any Equity Interests subsequently
issued upon conversion of Equity Interests issued upon exercise Series C Warrants. 

 (a) Prohibition Against Transfer of Equity Interests. 

(i) No Executive shall, directly or indirectly, sell, gift, transfer, assign, pledge, hypothecate, encumber, grant any
interest in or otherwise, directly or indirectly, dispose of (whether with or without consideration and whether voluntarily or involuntarily or by operation of law) (collectively, a “Transfer”) any of such Subject
Equityholder’s Equity Interests unless pursuant to a Public Sale or requirement resulting from the termination of such Executive’s employment with the Company or such Executive’s death or disability, including pursuant to any award
agreement, vesting agreement or similar agreement regarding the issuance of such Equity Interests to such Executive or otherwise in accordance with Sections 3, 4 or 5 hereof without first fulfilling the requirements of Sections 1 and 2 hereof.

 (ii) Founders shall not, directly or indirectly, Transfer any of such Subject Equityholder’s Equity
Interests other than pursuant to a Public Sale or in accordance with Sections 3, 4 or 5 hereof without first fulfilling the requirements of Sections 1 and 2 hereof. 

(iii) No holder of Common Stock (excluding Investors and former holders of Series A Preferred Stock, Series B Preferred
Stock or Series C Preferred Stock that receive shares of Common Stock upon conversion of Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock in accordance with the Certificate of Incorporation or otherwise acquire Common
Stock pursuant to an exercise of rights under this Agreement, a distribution or in any other manner) shall directly or indirectly Transfer any Equity Interests other than pursuant to a Public Sale, Section 3, 4 or 5 hereof. 

(b) Right of First Refusal. At least 45 days prior to any Subject Equityholder making any Transfer of any Equity
Interests, other than Transfers expressly permitted by Section 1(a)(i), (a)(ii) or (a)(iii) without fulfillment of the requirements of this Section and Section 2, the transferring Subject Equityholder (the “Transferring
Equityholder”) shall deliver an Offer Notice to the Investors and the holders of Series A Preferred Stock (excluding any Subject Equityholder) (“Offerees”). The Offer Notice shall be deemed to be an offer of the subject
Equity Interests to the Offerees on the same terms and conditions as proposed by the third party. The Offerees may elect to purchase all or a portion of the Equity Interests specified in the Offer Notice at the price and on the terms specified
therein by delivering written notice of such election to the Transferring Equityholder within 30 days after the delivery of the Offer Notice (the “Election Period”). If the Offerees in the aggregate elect to purchase a number of
Equity Interests in excess of the amount specified in the Offer Notice then such offered Equity Interests shall be allocated first to the Investors proportionately based on the number of shares of Series C Preferred Stock held by each and otherwise
issuable upon exercise of the Series C Warrants and second to the holders of Series A Preferred Stock proportionately based on the number of shares of Series A Preferred Stock owned by each of them. The purchase of the subject Equity Interests

  
 2 

 
shall be made in accordance with Section 1(c). In no event shall any Transfer of Equity Interests pursuant to this subsection be made for any consideration other than cash payable upon
consummation of such Transfer. No Subject Equityholder may Transfer Equity Interests pursuant to this subsection during the pendency of an Approved Sale regardless of the timing of an Offer Notice. 

(c) Procedures for Acquiring Equity Interests. The Transfer between the Transferring Equityholder and Offerees
electing to purchase Equity Interests in accordance with subsection (b) shall be consummated as soon as practical after the delivery of the election notices, but in any event within 15 days after the expiration of the Election Period. To the
extent that the Offerees have not elected to purchase all of the Equity Interests being offered under this Section, the Transferring Equityholder may, within 60 days after the expiration of the Election Period, Transfer any remaining Equity
Interests in accordance with and subject to the restrictions contained in the Certificate of Incorporation to one or more third parties at a price no less than the price per share specified in the Offer Notice and on other terms no more favorable to
the transferees than offered to the Offerees in the Offer Notice, and such purchases shall be conditioned upon receipt of approval from a Supermajority of the Series C Preferred Stock (which may be withheld for any reason or no reason) and receipt
from all purchasers of Equity Interests executing a counterpart of this Agreement. At the closing of the purchase of Equity Interests, the Transferring Equityholder shall provide representations and warranties as to its title to such securities and
that there are no liens or encumbrances on such securities and shall sign such stock powers and other documents as may reasonably be requested by the Offerees. 
 (d) Involuntary Transfers. Prior to a Public Offering or an Approved Sale, any event which, were it not for the provisions of this Agreement or the Certificate of Incorporation, would cause any
Equity Interests held by any Subject Equityholder to be Transferred to any party, whether voluntarily, involuntarily, or by operation of law (except as otherwise permitted by Section 1(a)) shall be deemed to constitute an offer to sell Equity
Interests held by such Subject Equityholder pursuant to Section 1(e) and such Subject Equityholder shall be deemed a Transferring Equityholder. 
 (e) Purchase Rights. Upon the occurrence of any event specified in Section 1(d), the Offerees shall have the right to purchase such Equity Interests at their Fair Market Value. Upon becoming
aware of any of the events set forth in Section 1(d), Offerees may, but shall not be obligated to, purchase all of the Equity Interests held by such Transferring Equityholder. The Offerees shall have the rights and be subject to the same terms
and conditions to purchase such Equity Interests as set forth in Sections 1(b) and 1(c) and the Transferring Equityholder shall be subject to the obligations to sell such Equity Interests thereunder. If the Offerees do not provide the Transferring
Equityholder timely notice of their election to purchase pursuant to Sections 1(b) within the 30-day election period in Section 1(b) commencing at the time the Offerees become aware of such occurrence, the Transferring Equityholder may retain
its Equity Interests and such securities shall remain subject to this Agreement. An Offeree may revoke any election to purchase Equity Interests under this Section, exercisable by written notice to such Subject Equityholder within 10 days after such
Offeree’s receipt of the determination of Fair Market Value for such Equity Interests. 

  
 3 

 2. Participation Rights. 

(a) At least 45 days prior to any Transfer of Equity Interests by any Subject Equityholder (other than a Transfer to the
Offerees pursuant to Section 1(b) or a permitted transfer under Sections 3 or 4 hereof), the Transferring Equityholder shall deliver a written notice (the “Sale Notice”) to the Offerees, specifying in reasonable detail the
identity of the prospective transferee(s), the amount of Equity Interests to be transferred and the terms and conditions of the Transfer (which notice may be the same notice and given at the same time as the Offer Notice under Section 1(b)).
The Offerees may elect to convert shares of Series A Preferred Stock , shares of Series B Preferred Stock or shares of Series C Preferred Stock to shares of Common Stock (including via exercise of Series C Warrants for shares of Series C Preferred
Stock with a subsequent conversion to shares of Common Stock pursuant to the Certificate of Incorporation) in a manner consistent with the optional conversion provisions of Section 3(f) of Article VI of the Certificate of Incorporation and
participate in the contemplated Transfer at the same price per share and on the same terms by delivering written notice to the Transferring Equityholder within 30 days after delivery of the Sale Notice. If any Offerees have elected to participate in
such Transfer, the Transferring Equityholder and such Offerees shall be entitled to sell in the contemplated Transfer, at the same price and on the same terms, an amount of Equity Interests equal to the product of (x) the quotient determined by
dividing the Percentage Ownership of such Equityholder by the aggregate Percentage Ownership of the Transferring Equityholder and the Offerees participating in such sale and (y) the amount of Equity Interests to be sold in the contemplated
Transfer (determined as if all Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (including the shares of Series C Preferred Stock issuable upon exercise of outstanding Series C Warrants) converted into Common Stock as
set forth in Section 3(f) of Article VI of the Certificate of Incorporation immediately prior to such Transfer). 
 (b) The Transferring Equityholder will use best efforts to obtain the agreement of the prospective purchaser(s) to the participation of the electing Offerees in any contemplated Transfer and the
Transferring Equityholder will not Transfer any shares to the prospective purchaser(s) unless: (i) the prospective purchaser(s) agree(s) to allow the participation of the electing Offerees; or (ii) the Transferring Equityholder agrees to
purchase the amount of shares from the electing Offerees that they would have been entitled to sell pursuant to this Section for the consideration per share to be paid to the Transferring Equityholder by the prospective transferee(s) simultaneously
with the closing of the Transfer of the Transferring Equityholder’s shares pursuant to the Sale Notice. Each Equityholder transferring Equity Interests pursuant to this Section: (A) shall pay its pro rata share (based on the amount of
Equity Interests to be sold) of the expenses incurred by the Equityholders in connection with such Transfer; (B) will only be required to make representations and warranties as to due power and authority, non-contravention and ownership of
Equity Interests, free and clear of all liens; and (C) shall be severally obligated to join on a pro rata basis (based on its share of the aggregate proceeds paid with respect to its interest) in any indemnification obligation the other
Equityholders have agreed to in connection with such sale other than any such obligation that relates specifically to a particular Equityholder, such as indemnification with respect to representations and warranties given by an Equityholder
regarding such Equityholder’s title to and ownership of Equity Interests; provided, that no Equityholder shall be obligated in connection with such sale to indemnify the prospective purchaser or its Affiliates with respect to an amount
in excess of the net cash proceeds paid to such Equityholder in connection with such sale (other than as a result of a breach of its representations and warranties described in clause (C), as to which no limitation shall apply).

  
 4 

 3. Restrictions on Transfer of Common Stock. 

(a) Except as set forth below, no holder of Common Stock may Transfer, either voluntarily or involuntarily, any or all of
such holder’s shares of Common Stock unless (a) such Transfer is approved by the Board of Directors and a Supermajority of the Series C Preferred Stock, which approval may be withheld or granted in the sole discretion of the Board of
Directors or Supermajority of the Series C Preferred Stock (as applicable), or (b) the Transferring holder of Common Stock complies with the provisions of this Agreement, or (c) the Transfer is described in Section 4 below.
Notwithstanding anything to the contrary contained herein, so long as a Transfer of Common Stock issued pursuant to Section 3(f) of Article VI of the Certificate of Incorporation of the Company complies with applicable securities laws, there
shall be no restrictions on the Transfer of such shares. 
 (b) The Corporation need not give effect to a
Transfer until it has notice of the Transfer, and it has been approved or made in accordance with this Agreement. 
 4.
Permitted Transfers of Common Stock. 
 (a) Any Transfer by a holder of Common Stock of his or her shares
of Common Stock to a “living trust,” as defined below, and any Transfer of an equity ownership interest in a holder of Common Stock that is an entity to a living trust by the individual who owns such entity ownership interest, shall be
permitted without consent and shall not be subject to the requirements of this Agreement, and, to the extent it holds shares of Common Stock, the living trust shall be bound by the provisions of this Agreement. For this purpose, a “living
trust” shall mean a trust of which the individual holder of Common Stock or the individual who owned the equity ownership interest in the holder of Common Stock that is an entity, as the case may be, is the sole grantor and sole initial
trustee, over which such individual has the full right of revocation, and which will function during the individual’s life primarily for the benefit of such individual. However, a subsequent amendment to the living trust that would do either of
the following: (i) remove the grantor individual as a trustee even though such individual is still alive and competent, or (ii) cause the living trust to function during such individual’s life other than primarily for such
individual’s benefit, shall be treated as a Transfer restricted as provided above. A change of the trustee of a living trust upon death of the grantor shall not be deemed a Transfer if the successor trustee or the primary beneficiary of the
living trust is an owner of an equity interest in a holder of Common Stock that is an entity. 
 (b) Any Transfer
by a holder of shares of Common Stock that is an entity to such entity’s equity security holders shall be permitted without consent, and each such equity security holder shall bound by the provisions of this Agreement. 

(c) Any involuntary Transfer by a holder of shares of Common Stock resulting from death of such holder, or any involuntary
Transfer of an equity ownership interest in a holder of shares of Common Stock that is an entity resulting from the death of the owner of such interest, to another holder of shares of Common Stock or owner of an equity ownership interest in a holder
of Common Stock that is an entity, shall be permitted without consent; provided that any subsequent Transfer shall be subject to this Agreement. 

  
 5 

 (d) For the avoidance of doubt, this Section 4 shall only apply to
Common Stock subject to the restriction on Transfer contained in Section 3 and does not apply to Transfers of shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock or any shares of Common Stock issued
pursuant to Section 3(f) of Article VI of the Certificate of Incorporation of the Company, all of which are freely transferable. 
 (e) Except as otherwise provided in Section 4(a) or (c), any Transfer of the ownership interest in a holder of shares of Common Stock that is an entity shall be deemed a Transfer of the shares of
Common Stock held by such holder of Common Stock that is an entity for purposes of this Agreement. 
 (f) With
respect to a Transfer of the ownership interest of TVAX Founders, LLC only, no Transfer shall constitute a Transfer of any shares of Common Stock of such entity so long as Gary W. Wood (or his estate or successor trustee if he is no longer living):
(i) continues to own, directly or indirectly, a majority of the outstanding ownership interest and voting securities of TVAX Founders, LLC (determined on a fully-diluted basis); (ii) either continues to serve as the sole manager of TVAX
Founders, LLC or maintains the right to designate and/or elect a majority of the managers of such entity; and (iii) maintains the right and ability to dictate in his sole discretion the exercise of all rights of TVAX Founders, LLC for all of
its Common Stock. 
 5. Drag-Along Rights. 

(a) The Company shall deliver an Offer Notice 20 days prior to the proposed date of any Approved Sale to each
Equityholder. Each holder of Voting Stock shall vote for, consent to and raise no objections to, and shall not bring a claim against or contest such Approved Sale. If the Approved Sale is structured as (i) a merger or consolidation, each holder
of Equity Interests shall waive any dissenters rights, appraisal rights or similar rights in connection with such merger or consolidation; or (ii) a sale of Equity Interests, each holder of Equity Interests shall (A) agree to sell all of
its Equity Interests and rights to acquire Equity Interests on the terms and conditions approved by the Board of Directors and the Supermajority of the Series C Preferred Stock subject to any additional consent requirements contained in the
Warrant Purchase Agreement and (B) execute such purchase agreement and other documents as executed by the Company and the parties that constitute a Supermajority of the Series C Preferred Stock. Each holder of Equity Interests shall take such
other necessary or desirable actions in connection with the consummation of the Approved Sale as reasonably requested by the Company or the Supermajority of the Series C Preferred Stock. 

(b) The obligations of the holders of Equity Interests with respect to the Approved Sale are subject to the satisfaction
of the following conditions (i) upon the consummation of the Approved Sale, each holder of Equity Interests shall receive for such party’s Equity Interests the same form of consideration and the same amount of consideration as the holders
of a majority of the Equity Interests receive for each of their Equity Interests whether 

  
 6 

 
directly as a result of a Transfer of Equity Interests or in a distribution of the proceeds of an asset sale; (ii) if any holders of a series of Equity Interests are given an option as to
the form and amount of consideration to be received whether directly as a result of a Transfer of Equity Interests or in a distribution of the proceeds of an asset sale, each holder of such series of Equity Interests shall be given the same option;
and (iii) each holder of then currently-exercisable rights to acquire Equity Interests shall be given an opportunity to either (A) exercise such rights prior to the consummation of the Approved Sale or (B) receive in exchange for such
rights consideration equal to the amount determined by multiplying (1) the same amount of consideration per share received by holders of such series of Equity Interests in connection with the Approved Sale less the exercise price or conversion
price per share of such series of Equity Interests by (2) the number of shares of such series of Equity Interests represented by such rights. 
 (c) Notwithstanding anything herein to the contrary, each Equityholder (i) will only be required to make representations and warranties as to due power and authority, non- contravention and ownership
of Equity Interests, free and clear of all liens and (ii) shall be severally obligated to join on a pro rata basis (based on its share of the aggregate proceeds paid with respect to its interest) in any indemnification obligation the other
Equityholders have agreed to in connection with such sale other than any such obligation that relates specifically to a particular Equityholder, such as indemnification with respect to representations and warranties given by a Equityholder regarding
such Equityholder’s title to and ownership of Equity Interests; provided, that no Equityholder shall be obligated in connection with such sale to indemnify the prospective transferee or its Affiliates with respect to an amount in excess
of the net cash proceeds paid to such Equityholder in connection with such sale (other than as a result of a breach of its representations and warranties described in clause (i), as to which no limitation shall apply). 

(d) The obligations of the Equityholders that hold Series C Warrants (the “Warrant Holders”) under this
Section and the right of the Equityholders exercisable under this Section is expressly subject to any put rights of the Warrant Holders contained in any of the Series C Warrants that Warrant Holders may exercise prior to an Approved Sale.

 (e) If at a closing of an Approved Sale, any Person selling shares shall fail to deliver any instruments or
documents required to be delivered in connection with the closing of such transaction, then delivery of the aggregate purchase price payable by any purchaser shall be made to the secretary of the Company or its successor (as applicable), as
attorney-in-fact for such Person. The secretary of the Company or its successor (as applicable) shall Transfer the appropriate shares on the books and records of the Company. From and after any such closing, such Person for all purposes shall no
longer be deemed to be the owner or holder of such transferred shares and shall have none of the rights or privileges of a holder thereof. The secretary of the Company or its successor (as applicable) shall hold the purchase price without interest
for such Person and shall deliver the same to such Person upon delivery of all instruments or documents required to be delivered in connection with the closing of such transaction. Each Equityholder hereby irrevocably designates and appoints the
secretary of the Company or its successor (as applicable) as such Person’s attorney-in-fact for purposes of effecting the intent of this paragraph and as such attorney-in-fact the secretary of the Company or its successor (as applicable) may
execute any and all instruments and documents necessary to Transfer ownership of shares in the manner described in this Section. The powers granted by 

  
 7 

 
each Equityholder pursuant to this paragraph are coupled with an interest and are given to secure the performance of each holder’s obligations under this Section. Such powers shall be
irrevocable and shall survive the death, incompetency, disability, bankruptcy or dissolution of such party. 
 6. Preemptive
Rights. Each time the Company proposes to sell or issue Equity Interests the Company shall also make an offering of such Equity Interests to the Investors and other holders of Series C Preferred Stock in accordance with the following provisions:

 (a) The Company shall deliver a notice to each Investor and other holder of Series C Preferred Stock stating
the amount of Equity Interests to be offered (and each such Investor’s and holder of Series C Preferred Stock’s proposed percentage allotment determined in accordance with subsection (b)) and the price and the terms on which it proposes to
offer such Equity Interests. Such notice shall be sent to the addresses set forth in the records of the Company. 

(b) Within 15 days after delivery of the notice, each Investor and holder of Series C Preferred Stock may elect to
purchase, at the price and on the terms specified in the notice delivered pursuant to subsection (a), up to its pro rata portion of such Equity Interests (based on the amount of Equity Interests held by such Investor and holder of Series C Preferred
Stock relative to the total number of outstanding Equity Interests of Equityholders) by delivering written notice of such election to the Company within such 15-day period. 

(c) The Investors and holders of Series C Preferred Stock electing to purchase their entire pro rata portion of Equity
Interests offered pursuant to this Section shall have the right to purchase all or any portion of the Equity Interests offered pursuant to this Section that other Investors or holders of Series C Preferred Stock did not elect to purchase under
subsection (b) on a “first come first served” basis for a period of 15 days after receipt of written notice from the Company notifying such Investors and holders of Series C Preferred Stock of the amount of Equity Interests that
Investors and holders of Series C Preferred Stock did not elect to purchase under subsection (b), at the price and on the terms specified in the notice delivered pursuant to subsection (a). 

(d) Any Equity Interests referred to in the notice that the Investors and holders of Series C Preferred Stock do not elect
to purchase as provided in subsections (b) and (c) may, during the 60-day period thereafter, be offered by the Company to any third parties at a price not less than, and on terms no more favorable to the offeree than, those specified in
the notice delivered pursuant to subsection (a). 
 (e) The preemptive rights set forth in this Section shall not
be applicable to the issuance of (i) up to 2,000,000 shares of Junior Common Stock issued to employees, consultants, officers or directors of the Company in accordance with the Certificate of Incorporation; (ii) up to 2,500,000 shares of
Common Stock that may be issued to employees or directors of, or consultants or advisors to, the Company pursuant to an employee benefit plan; (iii) shares of Series C Preferred Stock purchased by Biomedical from the Company to be used for the
redemption of Units of Biomedical issued upon the exercise or conversion of Series C Warrants as set forth in Section 12.21(b) of the Fourth Amended and Restated Operating Agreement of Biomedical; (iv) shares of Common Stock issued upon
the conversion of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock; and (v) shares of Series A Preferred Stock issued by the Company upon the conversion of Series B Preferred Stock. 

  
 8 

 (f) In lieu of using cash as purchase price consideration for the purchase
of Equity Interests under this Section, each Investor and holder of Series C Preferred Stock shall have the right to use its shares of Series C Preferred Stock, properly tendered and endorsed for Transfer to the Company, as purchase currency and
consideration. Each share of Series C Preferred Stock shall be deemed to have, for these purposes, a value equal to the Series C Original Issue Price for such share or the same value as any Equity Interest contained in the notice delivered pursuant
to subsection (a), whichever is greater (the “Deemed Value”). If an Investor or holder of Series C Preferred Stock elects to use Series C Warrants as purchase currency and consideration it shall make such election in the notice
delivered pursuant to subsection (b) by authorizing the Company to withhold from issuance an amount of Warrant Equity issuable upon such exercise of such Series C Warrant which when multiplied by the Deemed Value is equal to the purchase price
for the Equity Interests to be purchased under this Section (and such withheld shares shall no longer be issuable under such Series C Warrant). 
 (g) The application of this Section to any proposed sale or issuance of Equity Interests to which this Section would otherwise apply may be waived in a written instrument executed by each of the Initial
Investors, which waiver shall apply to all Investors and holders of Series C Preferred Stock. 
 7. Intentionally Omitted

 8. Intentionally Omitted 
 9. Demand Registrations. 
 (a) Requests for
Registration. Upon the first to occur of January 15, 2015 or the first Public Offering, the Investors may request registration under the Securities Act of all or part of Investor’s Registrable Securities on Form S-1 or any similar
long-form registration (“Long-Form Registrations”), and Equityholders may request registration under the Securities Act of all or part of the Registrable Securities on Form S-2 or S-3 or any similar short-form registration
(“Short-Form Registrations”) if available. All registrations requested pursuant to this subsection (a) are referred to herein as “Demand Registrations.” Each request for a Demand Registration shall specify the
approximate amount of Equity Interests requested to be registered and the requested per share price range, if any, for such offering. Investors may not request a Long-Form Registration unless Investors holding at least 50% of the Long-Form Demand
Registrable Securities then held by all Investors make such request to sell at least 25% of all Long-Form Demand Registrable Securities then held by all Investors. Equityholders may not request a Short-Form Registration for an amount of Registrable
Securities unless the aggregate offering value of the Registrable Securities subject to such request equals at least $500,000. 
 (b) Long-Form Registrations. The Investors shall be entitled to request two Long-Form Registrations in which the Company will pay all Registration Expenses. A registration will not count as one of
the permitted Long-Form Registrations until it has become effective, and no Long-Form Registration will count as one of the permitted Long-Form 

  
 9 

 
Registrations unless the Investors are able to register and sell at least 75% of the Equity Interests requested to be included in such registration; provided, that in any event the Company will
pay all Registration Expenses in connection with any registration initiated as a Long-Form Registration whether or not it has become effective. All Long-Form Registrations shall be underwritten registrations on a firm commitment basis. 

(c) Short-Form Registrations. In addition to the Long-Form Registrations provided pursuant to this Section, the
Equityholders shall be entitled to request two Short-Form Registrations each calendar year in which the Company will pay all Registration Expenses; provided, that the Company and the securities meet the eligibility requirements for such forms.
Demand Registrations shall be Short-Form Registrations whenever the Company is permitted to use any applicable short form. After the Company has become subject to the reporting requirements of the Exchange Act, the Company shall use its best efforts
to make Short-Form Registrations on Form S-3 available for the sale of Equity Interests. 
 (d) Priority on
Demand Registrations. Upon the Company’s commencement of a Demand Registration the Company shall mail notice thereof to all other Equityholders, and the other Equityholders shall have 20 days after such mailing date to notify the Company of
the amount of Registrable Securities they desire to sell in such offering. If the managing underwriters advise the Company in writing that in their opinion the number of registrable securities and, if permitted hereunder, other securities requested
to be included in such offering exceeds the number of securities which can be sold in an orderly manner in such offering within a price range acceptable to the Investors (or in the case of a Short-Form Registration initiated by other Equityholders
such other initiating Equityholders), the Company shall include in such registration prior to the inclusion of any securities which are not Long-Form Demand Registrable Securities the amount of Long-Form Demand Registrable Securities owned by the
Investors to be included which in the opinion of such underwriters can be sold in an orderly manner within the price range of such offering. If the full amount of the Long-Form Demand Registrable Securities of the Investors requested to be included
in such registration pursuant to this Section cannot be included in full, then the amount of Registrable Securities available for registration shall be allocated among the Investors pro rata based upon the amount of Long-Form Demand Registrable
Securities requested to be included in such registration by the Investors. 
 (e) Restrictions on Demand
Registrations. The Company shall not be obligated to effect any Demand Registration within 6 months after the effective date of a previous underwritten registration of Registrable Securities. The Company may postpone for up to 6 months the
filing or the effectiveness of a registration statement for a Demand Registration if the Company notifies the initiating Equityholders that such Demand Registration would reasonably be expected to have a material adverse effect on a pending material
transaction to which the Company is a party, as determined in the reasonable discretion of the Board of Directors exercising such discretion in good faith; provided, that in such event, the initiating Equityholders requesting such Demand
Registration will be entitled to withdraw such request and, if such request is a Long-Form Registration which is withdrawn, such Long-Form Registration will not count as one of the permitted Long-Form Registrations hereunder and otherwise such
Short-Form Registration shall not count as one of the two permitted Short-Form Registrations permitted in such calendar year and the Company shall pay all Registration Expenses in connection with such registration. 

  
 10 

 (f) Selection of Underwriters. The Investors shall have the right to
select the investment banker(s) and manager(s) to administer any Demand Registration. The Company will have the right to select the investment banker(s) and manager(s) to administer any offerings other than Demand Registrations. 

(g) Other Registration Rights. The Company shall not grant to any Person the right to request the Company to
register any Equity Interests that are senior or pari passu with the rights granted to the Investors under this Agreement without the consent of Investors holding a majority of the Long-Form Demand Registrable Securities. 

(h) Over-Allotment. Notwithstanding anything in this Section 9 to the contrary, the members of TVAX Investors,
LLC, a Kansas limited liability company, as of the date of this Agreement (the “Members of TVAX Investors”) may request registration under the Securities Act of all or part of the Registrable Securities held by the Members of TVAX
Investors on Form S-1 or any similar long-form registration and shall have priority to sell the Registrable Securities held by the Members of TVAX Investors in the event the managing underwriter exercises its over-allotment option in connection with
the Company’s first Public Offering. The right of the Members of TVAX Investors to sell any Registrable Securities pursuant to this Section shall be subject to the reasonable discretion of the managing underwriters, and subject to any
conditions reasonably requested by the managing underwriters. If the full amount of the Registrable Securities of the Members of TVAX Investors requested to be included in such sale pursuant to this Section cannot be included in full, then the
amount of Registrable Securities available for sale shall be allocated among the Members of TVAX Investors pro rata based upon the amount of Registrable Securities requested to be included in such sale by the Investors. 

10. Piggyback Registrations. 
 (a) Right to Piggyback. Subject to Section 9(h), whenever the Company proposes to register Equity Interests under the Securities Act pursuant to a Demand Registration or otherwise, (other
than, a transaction described under Rule 145 of the Securities Act, a transaction registering securities convertible into Equity Interests or pursuant to Form S-8 or its successor forms) and the registration form to be used may be used for the
registration of the Registrable Securities (a “Piggyback Registration”), the Company shall give prompt written notice to the Equityholders of its intention to effect such a registration and will include in such registration the
Registrable Securities of the Equityholders with respect to which the Company has received written requests for inclusion therein within 15 days after the receipt of the Company’s notice. 

(b) Piggyback Expenses. Subject to Section 9(h), the Registration Expenses of the Equityholders shall be paid
by the Company in all Piggyback Registrations. 
 (c) Priority on Primary Registrations. If a Piggyback
Registration is an underwritten primary registration on behalf of the Company, and the managing underwriters advise the Company in writing that in their opinion the number of securities requested to be included in such registration exceeds the
number which can be sold in such offering without adversely affecting the marketability of the offering, the Company shall include in such 

  
 11 

 
registration (i) first, the securities the Company proposes to sell, (ii) second, the securities requested by the Investors to be included in such registration, pro rata,
(iii) third, the securities requested by the Other Stockholders to be included in such registration, pro rata and (iv) fourth, the securities requested by any other parties to be included in such registration, pro rata. 

(d) Priority on Secondary Registrations. If a Piggyback Registration is an underwritten secondary registration on
behalf of holders of the Registrable Securities and the managing underwriters advise the Company in writing that in their opinion the number of securities requested to be included in such registration exceeds the number which can be sold in such
offering without adversely affecting the marketability of the offering, the Company shall include in such registration (i) first, the securities requested by the Investors to be included in such registration, pro rata, (ii) second, the
securities requested by the Other Stockholders to be included in such registration, pro rata, (iii) third, the securities requested by any other parties to be included in such registration, pro rata. and (iv) fourth, the securities the
Company proposes to sell. 
 (e) Proration of Eligible Shares. In the event of any registration pursuant
to this Section in which the full amount of the Registrable Securities of a particular group of Equityholders requested to be included in such registration cannot be included in full, then the amount of Registrable Securities available for
registration shall be allocated among such group pro rata based upon the amount of Registrable Securities requested to be included in such registration by each member of the group. 

11. Lockup Agreements. 
 (a) Each Equityholder agrees not to effect any Public Sale or distribution of Equity Interests, during the seven days prior to and the 90-day period beginning on the effective date of (i) any
underwritten offering of Equity Interests (except as part of such underwritten registration) or (ii) the Public Offering, in each case unless the underwriters managing the registered public offering and the Company otherwise agree. 

(b) The Company agrees (i) not to effect any Public Sale or distribution of Equity Interests during the 7 days prior
to and during the 90-day period beginning on the effective date of (A) any underwritten offering of Equity Interests (except as part of such underwritten registration) or (B) the Public Offering, unless the underwriters managing such
offering otherwise agree and (ii) to use its best efforts to cause each holder of Equity Interests at any time after the date of this Agreement to agree not to effect any Public Sale or distribution of any such securities during such period
(except as part of such underwritten registration, if otherwise permitted), unless the underwriters managing such offering otherwise agree. 

  
 12 

 12. Registration Procedures. Whenever any securities are registered pursuant to this
Agreement, the Company shall use its best efforts at its expense to effect the registration and the sale of such securities in accordance with the intended method of disposition thereof, and pursuant thereto the Company shall as expeditiously as
possible: 
 (a) prepare and file with the Securities and Exchange Commission a registration statement with
respect to such securities and use its best efforts to cause such registration statement to become effective; provided, that before filing a registration statement or prospectus or any amendments or supplements thereto, the Company shall
furnish to the counsel selected by the Investors holding a majority of the Long-Form Demand Registrable Securities covered by such registration statement, or if none, selected by the Other Stockholders holding a majority of the Registrable
Securities covered by such registration statement, copies of all such documents proposed to be filed, which documents will be subject to the review and comment of such counsel; 

(b) prepare and file with the Securities and Exchange Commission such amendments and supplements to such registration
statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective for a period of not less than 9 months and comply with the provisions of the Securities Act with respect to the disposition
of all securities covered by such registration statement during such period in accordance with the intended methods of disposition by the sellers thereof set forth in such registration statement; 

(c) furnish to each seller of securities such number of copies of such registration statement, each amendment and
supplement thereto, the prospectus included in such registration statement (including each preliminary prospectus) and such other documents as such seller may reasonably request in order to facilitate the disposition of the securities owned by such
seller; 
 (d) use its best efforts to register or qualify such securities under such other securities or blue
sky laws of such jurisdictions as any seller reasonably requests and do any and all other acts and things which may be reasonably necessary or advisable to enable such seller to consummate the disposition in such jurisdictions of the securities
owned by such seller; provided, that the Company shall not be required to (i) qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this subparagraph, (ii) subject itself to
taxation in any such jurisdiction or (iii) consent to general service of process in any such jurisdiction; 

(e) notify each seller of Equity Interests, at any time when a prospectus relating thereto is required to be delivered
under the Securities Act, of the happening of any event as a result of which the prospectus included in such registration statement contains an untrue statement of a material fact or omits any fact necessary to make the statements therein not
misleading, and, at the request of any such seller, the Company shall prepare a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of such Equity Interests, such prospectus will not contain an untrue
statement of a material fact or omit to state any fact necessary to make the statements therein not misleading; 

(f) cause all such securities to be listed on each securities exchange on which similar securities issued by the Company
are then listed; 
 (g) provide a transfer agent and registrar for all such securities not later than the
effective date of such registration statement; 

  
 13 

 (h) enter into such customary agreements (including underwriting agreements
in customary form) and take all such other actions as the Investors holding a majority of the Long-Form Demand Registrable Securities covered by such registration statement, or if none, selected by the Other Stockholders holding a majority of the
Registrable Securities covered by such registration statement or the underwriters, if any, reasonably request in order to expedite or facilitate the disposition of such securities (including, without limitation, effecting a conversion of the Company
to a corporation, if applicable, equity split or a combination of Equity Interests); 
 (i) make available for
inspection by any seller of securities, any underwriter participating in any disposition pursuant to such registration statement and any attorney, accountant or other agent retained by any such seller or underwriter, all financial and other records,
pertinent company documents and properties of the Company, and cause the Company’s officers, directors, managers, employees and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney,
accountant or agent in connection with such registration statement; 
 (j) otherwise use its best efforts to
comply with all applicable rules and regulations of the Securities and Exchange Commission, and make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least 12 months beginning with
the first day of the Company’s first full calendar quarter after the effective date of the registration statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder;

 (k) permit any Equityholder which might be deemed to be an underwriter or a controlling person of the Company,
to participate in the preparation of such registration or comparable statement and to require the insertion therein of material, furnished to the Company in writing, which in the reasonable judgment of such Equityholder should be included;

 (l) in the event of the issuance of any stop order suspending the effectiveness of a registration statement,
or of any order suspending or preventing the use of any related prospectus or suspending the qualification of any Equity Interests included in such registration statement for sale in any jurisdiction, the Company shall use its best efforts promptly
to obtain the withdrawal of such order; and 
 (m) obtain a cold comfort letter from the Company’s
independent public accountants in customary form and covering such matters of the type customarily covered by cold comfort letters as any Equityholders may reasonably request. 
 13. Registration Expenses. 
 (a) All expenses incident to
the Company’s performance of or compliance with, the registration rights contained in this Agreement, including, without limitation, all registration and filing fees, fees and expenses of compliance with securities or blue sky laws, printing
expenses, messenger and delivery expenses, and fees and disbursements of counsel for the Company and all independent certified public accountants, underwriters (excluding discounts and commissions) and other parties retained by the Company (all such
expenses being herein called “Registration Expenses”), shall be borne as provided in this Agreement, except that the 

  
 14 

 
Company shall, in any event, pay its internal expenses (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense
of any annual audit or quarterly review, the expense of any liability insurance and the expenses and fees for listing the securities to be registered on each securities exchange on which similar securities issued by the Company are then listed.

 (b) In connection with each Demand Registration, the Company shall reimburse the Investors or Other
Stockholders (as applicable), with regard to their separate Demand Registration right, for the reasonable fees and disbursements of one counsel to the extent either the Investors or Other Stockholders, with regard to their separate Demand
Registration right, request separate counsel from the Company. 
 (c) To the extent Registration Expenses are not
required to be paid by the Company, each holder of securities included in any registration hereunder shall pay those Registration Expenses allocable to the registration of such holder’s securities so included, and any Registration Expenses not
so allocable shall be borne by all sellers of securities included in such registration in proportion to the aggregate selling price of the securities to be so registered. 
 14. Indemnification. 
 (a) The Company agrees to indemnify,
to the extent permitted by law, the Equityholders, their officers, managers, partners and directors and each of their Affiliates against all losses, claims, damages, liabilities and expenses caused by any untrue or alleged untrue statement of
material fact contained in any registration statement, prospectus or preliminary prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the
statements therein not misleading, except indemnification shall not be provided to an Equityholder insofar as the same are caused by or contained in any information furnished in writing to the Company by the Equityholder expressly for use therein or
by the Equityholder’s failure to deliver a copy of the registration statement or prospectus or any amendments or supplements thereto after the Company has furnished the Equityholder with a sufficient number of copies of the same. In connection
with an underwritten offering, the Company shall indemnify such underwriters, their officers and directors and each of their Affiliates to the same extent as provided above with respect to the indemnification of the Equityholders. 

(b) In connection with any registration statement in which an Equityholder is participating, each such Equityholder shall
furnish to the Company in writing such powers of attorney, custody agreements and letters of direction and other information and affidavits as the Company reasonably requests for use in connection with any such registration statement or prospectus
and, to the extent permitted by law, shall only have to indemnify the Company, its directors and officers and their Affiliates against any losses, claims, damages, liabilities and expenses resulting from any untrue or alleged untrue statement of
material fact contained in the registration statement, prospectus or preliminary prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the
statements therein not misleading, but only to the extent that such untrue statement or omission is contained in any information or affidavit so furnished in writing by such Equityholder to the Company for specific use in such registration
statement, 

  
 15 

 
prospectus or amendment or supplement thereto and which remained in the final prospectus delivered to the purchaser of such securities; provided, that the obligation to indemnify shall be
limited to the net amount of proceeds received by such Equityholder from the sale of Equity Interests pursuant to such registration statement. 
 (c) Any party entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) unless in
such indemnified party’s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying party to assume the defense of such claim with counsel
reasonably satisfactory to the indemnified party. If such defense is assumed, the indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its consent (but such consent shall not be
unreasonably withheld). An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and expenses of more than one counsel for all parties indemnified by such indemnifying party
with respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other of such indemnified parties with respect to such claim. 

(d) The indemnification provided for under this Agreement shall remain in full force and effect regardless of any
investigation made by or on behalf of the indemnified party or any officer, director, manager, partner or Affiliate of such indemnified party and shall survive the Transfer of securities. The Company also agrees to make such provisions, as are
reasonably requested by any indemnified party, for contribution to such party in the event the Company’s indemnification is unavailable for any reason. 
 15. Participation in Underwritten Registrations. No Equityholder may participate in any registration hereunder which is underwritten unless such Equityholder (i) agrees to sell such its
securities on the basis provided in any underwriting arrangements approved by the parties entitled hereunder to approve such arrangements and (ii) completes and executes all questionnaires, powers of attorney, indemnities, underwriting
agreements and other documents required under the terms of such underwriting arrangements; provided, that no Equityholder shall be required to make any representations or warranties to the Company or the underwriters other than
representations and warranties regarding such Equityholder’s intended method of distribution. 
 16. Legend. Each
certificate evidencing Equity Interests and each certificate issued in exchange for or upon the Transfer of any Equity Interests (if such shares remain Equity Interests as defined herein after such transfer) shall be stamped or otherwise imprinted
with legends in substantially the following form (as applicable): 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR AN EXEMPTION FROM REGISTRATION THEREUNDER. 

  
 16 

 THE SECURITIES REPRESENTED BY THIS CERTIFICATE WERE ORIGINALLY ISSUED ON
[    ], [    ], AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THE TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE CONDITIONS SPECIFIED IN THE INVESTOR
RIGHTS AGREEMENT, DATED AS OF JULY 15, 2011 AND AS AMENDED AND MODIFIED FROM TIME TO TIME, AMONG THE ISSUER AND THE HOLDERS PARTY THERETO, AND THE ISSUER RESERVES THE RIGHT TO REFUSE THE TRANSFER OF SUCH SECURITY UNTIL SUCH CONDITIONS HAVE BEEN
FULFILLED WITH RESPECT TO SUCH TRANSFER. UPON WRITTEN REQUEST, A COPY OF SUCH CONDITIONS SHALL BE FURNISHED BY THE COMPANY TO THE HOLDER HEREOF WITHOUT CHARGE. 
 The Company shall imprint such legends on certificates evidencing outstanding Equity Interests. The legends set forth above shall be removed from the certificates evidencing any Equity Interests that are
no longer subject to the terms of this Agreement in accordance with the terms of this Agreement. 
 17. Actions Consistent
with Agreement. The Company shall not circumvent this Agreement by taking any action through an Affiliate that would be prohibited under this Agreement. Neither the Certificate of Incorporation nor the Bylaws shall be amended in any manner that
would conflict with, or be inconsistent with, the provisions of this Agreement. 
 18. Transfer. Prior to transferring
any Equity Interests (other than in a Public Sale or Approved Sale) to any party pursuant to the terms of this Agreement, the transferring Equityholder shall cause the prospective transferee to execute and deliver to the Company and the other
Equityholders a counterpart of this Agreement. Each such counterpart shall be deemed to be an original part of this Agreement as though executed on the date hereof Upon the execution of this Agreement: (a) the transferee shall be treated as an
Investor if the majority of its Equity Interests were acquired from the Investors; or (b) the transferee shall be treated as an Other Stockholder if the majority of its Equity Interests were acquired from the Other Stockholders. If a transferee
(other than an Investor, holder of shares of Series A Preferred Stock, Series B Preferred Stock or holder of Series C Preferred Stock) acquired Equity Interests subject to the restrictions on Transfer contained in Sections 1 and 2 from an Other
Stockholder, then Transfers of such Equity Interests shall continue to be bound by Sections 1 and 2. 
 19. Definitions.

 “Approved Sale” means a Sale of the Company approved by each of the Board of Directors and the Initial
Investors. 
 “Equity Interests” means (i) any equity securities issued by the Company purchased or
otherwise acquired by any Equityholder (including, without limitation, Convertible Securities, Series C Warrants and other rights containing phantom or other equity participation features) or (ii) any equity securities issued or issuable with
respect to the securities referred to in clause (i) above by way of distribution or split or in connection with a combination of securities, 

  
 17 

 
recapitalization, merger, consolidation or other reorganization. For purposes of this Agreement, any party that holds any Convertible Securities of the Company, including Series C Warrants shall
be deemed to be the holder of the underlying equity securities obtainable upon the conversion or exercise of such Convertible Securities including Series C Warrants in connection with the Transfer thereof or otherwise regardless of any restriction
or limitation on the conversion or exercise of such Convertible Securities including Series C Warrants, such underlying equity securities shall be deemed to be in existence, and such party shall be entitled to exercise the rights of a holder of such
underlying equity securities hereunder. As to any particular Equity Interests, such shares shall cease to be Equity Interests when they have been sold to the public through a Public Sale even if thereafter they are reacquired by an Equityholder.

 “Executive” means any employee, consultant, officer or director of the Company that receives, directly or
indirectly, any Equity Interests in respect of employment with or services performed for the Company, and specifically includes Gary W. Wood, Rex Wiggins, Timothy Wurst and Catherine Lucasey. 

“Fair Market Value” means the fair market value of shares of Common Stock, determined on a going concern basis as
between a willing buyer and a willing seller and taking into account all relevant factors determinative of value without giving effect to any discount for any lack of liquidity attributable to a lack of a public market for such security, any block
discount or discount attributable to the size of any Person’s holdings of such security, any minority interest or any voting rights thereof or lack thereof. The Offerees and the subject Equityholders will use reasonable efforts to determine
Fair Market Value, but if such parties are unable to agree on Fair Market Value within 10 days after meeting for the purpose of determining the Fair Market Value, the Offerees and the subject Equityholders shall, within 20 days after the event
causing the need for a determination of Fair Market Value, mutually select an appraiser to make a determination of the Fair Market Value (who shall make such determination within 30 days after selection). If the Offerees and the subject
Equityholders are unable to agree on an appraiser within a reasonable period of time, then the parties shall choose the appraiser by lot with each of them choosing 2 appraisers and the appraiser chosen by lot from those 4 appraisers. The
determination of such appraiser shall be final and binding upon the parties, and the fees and expenses of such appraiser shall be borne by the Company. 
 “Founders” means TVAX Founders, LLC. 
 “Independent Third
Party” means any party who, immediately prior to the contemplated transaction, does not own in excess of 5% of the Equity Interests (a “5% Owner”), who is not an Affiliate of any such 5% Owner and who is not the spouse or
descendent (by birth or adoption) of any such 5% Owner or a trust for the benefit of such 5% Owner and/or such other persons. 

“Initial Investors” means TVAX Investors, LLC or upon the dissolution or liquidation of TVAX Investors, LLC former
holders of at least 70% of Underlying Equity (as defined in the Warrant Purchase Agreement) distributed to members of TVAX Investors, LLC (whether as a distribution of Series C Warrants and/or shares of Series C Preferred Stock formerly held by TVAX
Investors, LLC). 

  
 18 

 “Long-Form Demand Registrable Securities” means shares of Common Stock now
or hereafter acquired by Investors, including all shares of Common Stock issuable upon conversion or exercise of shares or any option, warrants or other rights, directly or indirectly, to acquire shares of Common Stock. 

“Offer Notice” shall mean the notice required to be given by a Transferring Equityholder to the Offerees or in the event
of an Approved Sale, by the Company to each Equityholder, describing a proposed Transfer or Approved Sale, as the case may be. At a minimum, the Offer Notice shall be in writing and shall contain (i) the amount of Equity Interests that the
Transferring Equityholder or the Company proposes to sell or requires to be sold, as applicable, (ii) the name and address of the proposed transferee, and (iii) the proposed purchase price, terms of payment and other material terms and
conditions of such proposed transfer. 
 “Percentage Ownership” of an Equityholder means the number of shares
held by such Equityholder divided by the number of shares of all Equityholders. 
 “Public Offering” means the
sale in an initial public offering registered under the Securities Act of Equity Interests. 
 “Public Sale”
means any sale of Equity Interests to the public pursuant to an offering registered under the Securities Act or to the public through a broker, dealer or market maker pursuant to the provisions of Rule 144 adopted under the Securities Act.

 “Registrable Securities” means Long-Form Demand Registrable Securities and any shares of Common Stock now or
hereafter acquired by Other Stockholders, including all shares of Common Stock issuable upon conversion or exercise of shares or any option, warrants or other rights, directly or indirectly, to acquire shares of Common Stock. Shares of Junior Common
Stock are not Registrable Securities. 
 “Sale of the Company” means the sale of the Company to an Independent
Third Party or group of Independent Third Parties pursuant to which such party or parties acquire (i) Equity Interests possessing the voting power under normal circumstances to elect a majority of the Board (whether by merger, consolidation or
sale or Transfer of the Equity Interests) or (ii) all or substantially all of the Company’s assets determined on a consolidated basis. 
 “Securities and Exchange Commission” includes any governmental body or agency succeeding to the functions thereof. 

“Warrant Equity” shall have the same meaning assigned to such term as in the certificates evidencing the Series C
Warrants. 
 20. Transfers in Violation of Agreement. Any Transfer or attempted Transfer of any Equity Interests in
violation of any provision of this Agreement shall be void, and the Company shall not record such Transfer on its books or treat any purported transferee of such Equity Interests as the owner of such Equity Interests for any purpose. 

  
 19 

 21. Amendment and Waiver. This Agreement may be amended or waived from time to time
by a written instrument executed by the Initial Investors and the Company. Notwithstanding the foregoing, the Company may from time to time add additional Equityholders to this Agreement without the consent or additional signatures of the parties
hereto (and amend and/or restate the Agreement to reflect such additions) and upon the Company’s receipt of such additional Equityholders’ signature pages, such additional Equityholders shall be deemed to be a party hereto and such
additional signature pages shall be a part of this Agreement. The failure of any party to enforce any of the provisions of this Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right of such party
thereafter to enforce each and every provision of this Agreement in accordance with its terms. 
 22. Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under
any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if
such invalid, illegal or unenforceable provision had never been contained herein. 
 23. Complete Agreement. This
Agreement, those documents expressly referred to herein, and the other documents of even date herewith delivered or executed in connection with the transactions contemplated by the Note Purchase Agreement embody the complete agreement and
understanding among the parties and supersede any prior agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way. 

24. Successors and Assigns. Except as otherwise provided herein, this Agreement shall bind and inure to the benefit of and be
enforceable by the Company and its successors and assigns and the Equityholders and holders of Series C Warrants and Warrant Equity and any permitted subsequent holders of Equity Interests, Series C Warrants and/or Warrant Equity and the respective
successors and permitted assigns of each of them, so long as they hold Equity Interests, Series C Warrants, or Warrant Equity. Specifically, following the restructuring of the ownership of Biomedical and the organization and capitalization of the
Company, Investors intends to distribute to its members all of its shares of Series C Preferred Stock of the Company and the Series C Warrants of Biomedical, at which time this Agreement shall bind and inure to the benefit of, and be enforceable by,
such members of Investors and their successors and assigns. 
 25. Counterparts. This Agreement may be executed in
separate counterparts each of which shall be an original and all of which taken together shall constitute one and the same agreement. 
 26. Remedies. The parties hereto shall be entitled to enforce their rights under this Agreement specifically, to recover damages by reason of any breach of any provision of this Agreement and to
exercise all other rights existing in their favor. The parties hereto agree and acknowledge that money damages may not be an adequate remedy for any breach of the provisions of this Agreement and that any of the parties hereto may in its sole
discretion apply to any court of law or equity of competent jurisdiction for specific performance and/or injunctive relief (without posting a bond or other security) in order to enforce or prevent any violation of the provisions of this Agreement.

  
 20 

 27. Notice. Any notice provided for in this Agreement shall be in writing and shall
be either personally delivered, or mailed first class mail (postage prepaid) or sent by reputable overnight courier service (charges prepaid) to the Company at its principal executive office address and to any other recipient at the address
indicated on the signature pages hereto and to any subsequent holder of Equity Interests subject to this Agreement at such address as indicated by the Company’s records, or at such address or to the attention of such other person as the
recipient party has specified by prior written notice to the sending party. Notices will be deemed to have been given hereunder when delivered personally, three days after deposit in the U.S. mail and one day after deposit with a reputable overnight
courier service. 
 28. Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of
the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the
State of Delaware. In furtherance of the foregoing, the internal law of the State of Delaware shall control the interpretation and construction of this Agreement (and all schedules and exhibits hereto), even though under that jurisdiction’s
choice of law or conflict of law analysis, the substantive law of some other jurisdiction would ordinarily apply. 
 29.
Other Interpretive Matters. Unless a clear contrary intention appears: (a) the singular number includes the plural number and vice versa; (b) reference to any party includes such party’s successors and assigns but, if
applicable, only if such successors and assigns are permitted by this Agreement, and reference to a party in a particular capacity excludes such party in any other capacity or individually; (c) reference to any gender includes each other
gender, the masculine, the feminine and neuter; (d) reference to any agreement (including this Agreement), document or instrument means such agreement, document or instrument as amended or modified and in effect from time to time in accordance
with the terms thereof and, if applicable, the terms hereof (and without giving effect to any amendment or modification that would not be permitted in accordance with the terms hereof); (e) reference to any applicable law means such applicable
law as amended, modified, codified or reenacted, in whole or in part, and in effect from time to time, including rules and regulations promulgated thereunder and reference to any particular provision of any applicable law shall be interpreted to
include any revision of or successor to that provision regardless of how numbered or classified; (f) reference to any Section means such Section hereof; (g) “hereunder,” “hereof,” “hereto” and words of similar
import shall be deemed references to this Agreement as a whole and not to any particular Section or other provision hereof; (h) “including” (and with correlative meaning “include”) means including without limiting the
generality of any description preceding such term; (i) relative to the determining of any period of time, “from” means “from and including” and “to” and “through” mean “to and including”;
(j) “or”, “either” and “any” are not exclusive; and (k) references to any Subsidiary of a party shall be given effect only at such times as such party has one or more Subsidiaries. 

  
 21 

 30. Termination. The provisions of Sections 1 through 6 shall terminate on the
consummation of a Public Offering (or, with respect to an Equity Interest, the date such Equity Interest has been transferred in a Public Sale) with the remaining provisions of this Agreement terminating on the sixth anniversary of the consummation
of a Public Offering. This Agreement shall also terminate in its entirety upon the consummation of an Approved Sale. 
 31.
Construction. The parties hereto have participated in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted by the parties
hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. 

  
 22 

 IN WITNESS WHEREOF, the parties hereto have executed this Investor Rights Agreement on the
day and year first above written. 
  

			
	COMPANY:
	
	TVAX BIOMEDICAL, INC.
		
	By:	 	/s/ Gary W. Wood
	Name:	 	Gary W. Wood
	Title:	 	CEO

  

			
	 OTHER STOCKHOLDERS
 Each of the Stockholders identified on Schedule A,
 pursuant to Power of
Attorney

	
	/s/ Gary W. Wood
	Gary W. Wood, Attorney in Fact

  

			
	BIOMEDICAL:
	
	TVAX BIOMEDICAL I, LLC
		
	By:	 	/s/ Gary W. Wood
	Name:	 	Gary W. Wood
	Title:	 	CEO

 [SIGNATURES CONTINUED ON NEXT PAGE] 

 
			
	 INVESTORS:
  

TVAX INVESTORS, LLC

		
	By:	 	/s/ Larry C. Maddox
	Name:	 	Larry C. Maddox, Manager
	Title:	 	Managing Member

  

			
	 Address:
  

c/o Bryan Cave LLP
 3500 One Kansas City
Place
 1200 Main Street
 Kansas City,
Missouri 64105
 Attention: Robert M. Barnes
  

The James P. Pace Trust under Declaration of
 Trust dated February 7, 1992

	
	/s/ James P. Pace
	James P. Pace, Trustee

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]